دورية أكاديمية

Plasma monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1α are increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatment.

التفاصيل البيبلوغرافية
العنوان: Plasma monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1α are increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatment.
المؤلفون: Glintborg, Dorte, Andersen, Marianne, Richelsen, Bjørn, Bruun, Jens M.
المصدر: Clinical Endocrinology; Nov2009, Vol. 71 Issue 5, p652-658, 7p, 2 Charts, 1 Graph
مصطلحات موضوعية: POLYCYSTIC ovary syndrome, MONOCYTES, MACROPHAGES, OBESITY, INSULIN resistance, BLOOD plasma, CHEMOKINES
مستخلص: Objective Hirsutism is most often caused by polycystic ovary syndrome (PCOS). PCOS patients are characterized by insulin resistance, abdominal obesity and low-grade inflammation. Insulin sensitizing treatment reduces the inflammatory state, but the effect on serum levels of migration inhibitor factor (MIF), monocyte chemoattractant protein (MCP)-1 and macrophage inflammatory protein (MIP)-1α have not been evaluated before in PCOS. Research design and methods Plasma chemokine levels (MCP-1, MIP-1α and MIF) were measured in two study designs. (i) 51 hirsute patients and 63 matched controls and (ii) 30 PCOS patients before and after randomized treatment with 30 mg pioglitazone/placebo for 16 weeks. Clinical evaluations and whole body DXA-scans were performed in all participants. Results Hirsute patients ( n = 51) had significantly increased MCP-1 [121 (15–950) vs. 81 (18–365) pg/ml; P < 0·05] and MIP-1α[179 (8–4202) vs. 103 (4–1598) pg/ml; P < 0·05] than controls of matched body composition [geometric mean (–2SD to +2SD)]. In PCOS ( n = 30), MCP-1, MIP-1α and MIF correlated positively with central fat mass. A BMI independent positive association was found between MIF and free testosterone ( r = 0·49, P = 0·01) in PCOS. Pioglitazone treatment significantly improved insulin sensitivity without affecting testosterone, body composition, MCP-1, MIP-1α and MIF levels. Conclusions Chemokine levels were significantly increased and showed close associations with measures of adiposity in PCOS patients, but were unchanged during insulin sensitizing treatment with pioglitazone. Our data suggests a fat mass independent association between testosterone and MIF levels in PCOS and the effect of anti-androgen treatment on chemokine levels needs to be examined. [ABSTRACT FROM AUTHOR]
Copyright of Clinical Endocrinology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:03000664
DOI:10.1111/j.1365-2265.2009.03523.x